Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis

J Infect Dis. 2000 Jul;182(1):371-4. doi: 10.1086/315645. Epub 2000 Jun 30.

Abstract

There is no consensus on the benefits of treatment with any specific anthelminthic compound on muscle-stage trichinosis. A double-blind, placebo-controlled comparison was done of 3 antiparasitic drugs during an outbreak of trichinosis in Chiangrai Province, northern Thailand. Forty-six adults were randomized to receive 10 days of oral treatment with mebendazole (200 mg twice a day), thiabendazole (25 mg/kg twice a day), fluconazole (400 mg initially, then 200 mg daily), or placebo. All patients received treatment to eradicate adult intestinal worms. Trichinella spiralis infection was proved parasitologically in 19 (41%) of 46 patient and by serodiagnosis in all cases. Significantly more patients improved after treatment with mebendazole (12/12) and thiabendazole (7/7) than after treatment with placebo (6/12; P<.05) or fluconazole (6/12). Muscle tenderness resolved in more patients treated with thiabendazole and mebendazole than in those treated with placebo (P<.05). However, 30% of volunteers could not tolerate the side effects of thiabendazole. In summary, Trichinella myositis responds to thiabendazole and to mebendazole.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Antinematodal Agents / therapeutic use*
  • Double-Blind Method
  • Female
  • Fluconazole / therapeutic use
  • Humans
  • Male
  • Mebendazole / therapeutic use*
  • Myositis / diagnosis
  • Myositis / drug therapy*
  • Myositis / parasitology
  • Thiabendazole / therapeutic use
  • Treatment Outcome
  • Trichinellosis / diagnosis
  • Trichinellosis / drug therapy*

Substances

  • Antinematodal Agents
  • Mebendazole
  • Fluconazole
  • Thiabendazole